



**December 11, 2025**

**Announcement no. 29**

### **Changes to the Executive Management**

COPENHAGEN, DENMARK and BOSTON, MA, USA, December 11, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto”) (CPH:BIOPOR) announced today that Niels Høy Nielsen has resigned as CFO of BioPorto to become CFO at another company.

“I have valued the close collaboration with Niels during the last couple of months since I joined BioPorto. He has made important contributions across the company and wish him all the best in his future endeavors” said Carsten Buhl, BioPorto’s Chief Executive Officer.

Niels Høy Nielsen will continue to serve in his current role at the Company through March 2026. The Company will evaluate its future organizational structure in due course.

To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on <https://bioporto.com/investor-contact/>.

### **Investor Relations contacts**

Carsten Buhl, BioPorto A/S, [investor@bioporto.com](mailto:investor@bioporto.com), C: +45 45290000

### **About BioPorto**

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit [www.bioporto.com](http://www.bioporto.com).